← 產業報告目錄
Parkinson’s Disease Therapeutic Market Size, Share & Trends Analysis Report By Drugs (Carbidopa-levodopa, Dopamine agonists, Mao-b inhibitors, COMT inhibitors, Anticholinergics), By Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy), By Brand, By Route of Administration, By Region, And By Segment Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-08頁數 170報告編號 INSIGHTACE-1c230deb18
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
With a 2023 valuation of USD 4.22 billion, the global Parkinson’s Disease Therapeutic Market is anticipated to expand to USD 6.51 billion by 2031, demonstrating a CAGR of 5.7% during the 2024–2031 forecast window.
At its core, Parkinson’s Disease Therapeutic pertains to attributed to the loss of neurons in the part of the brain responsible for motor control. Stakeholders across the healthcare landscape are surgingly turning to these solutions to meet contemporary demands.
Several factors contribute to this trajectory, including heightened need next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region anticipated to deliver the strongest growth trajectory through the forecast period, fueled by demographic shifts and policy support.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Parkinson's Disease Therapeutic Market Snapshot
Chapter 4. Global Parkinson's Disease Therapeutic Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Drug Class Estimates & Trend Analysis
5.1. By Drug Class & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Drug Class:
5.2.1. Carbidopa-levodopa
5.2.2. Dopamine Agonists
5.2.3. MAO-B Inhibitors
5.2.4. COMT inhibitors
5.2.5. Anticholinergics
5.2.6. Others
Chapter 6. Market Segmentation 2: By Brand Estimates & Trend Analysis
6.1. By Brand & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Brand:
6.2.1. Branded
6.2.2. Generics
Chapter 7. Market Segmentation 3: By Distribution Channel Estimates & Trend Analysis
7.1. By Distribution Channel & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Distribution Channel:
7.2.1. Hospital Pharmacy
7.2.2. Retail Pharmacy
7.2.3. Online Pharmacy
Chapter 8. Market Segmentation 4: By Route of Administration Estimates & Trend Analysis
8.1. By Route of Administration & Market Share, 2019 & 2031
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Route of Administration:
8.2.1. Oral
8.2.2. Injectable
8.2.3. Intestinal Infusion
8.2.4. Subcutaneous
8.2.5. Others
Chapter 9. Parkinson's Disease Therapeutic Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts By Drug Class, 2024-2031
9.1.2. North America Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts By Brand, 2024-2031
9.1.3. North America Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts By Distribution Channel, 2024-2031
9.1.4. North America Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2024-2031
9.1.5. North America Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.2. Europe
9.2.1. Europe Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts By Drug Class, 2024-2031
9.2.2. Europe Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts By Brand, 2024-2031
9.2.3. Europe Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts By Distribution Channel, 2024-2031
9.2.4. Europe Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2024-2031
9.2.5. Europe Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.3. Asia Pacific
9.3.1. Asia Pacific Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts By Drug Class, 2024-2031
9.3.2. Asia Pacific Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts By Brand, 2024-2031
9.3.3. Asia-Pacific Thermal Cyclers Asia-Pacific Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts By Distribution Channel, 2024-2031
9.3.4. Asia-Pacific Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2024-2031
9.3.5. Asia Pacific Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.4. Latin America
9.4.1. Latin America Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts By Drug Class, 2024-2031
9.4.2. Latin America Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts By Brand, 2024-2031
9.4.3. Latin America Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts By Distribution Channel, 2024-2031
9.4.4. Latin America Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2024-2031
9.4.5. Latin America Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.5. Middle East & Africa
9.5.1. Middle East & Africa Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts By Drug Class, 2024-2031
9.5.2. Middle East & Africa Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts By Brand, 2024-2031
9.5.3. Middle East & Africa Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts By Distribution Channel, 2024-2031
9.5.4. Middle East & Africa Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2024-2031
9.5.5. Middle East & Africa Parkinson's Disease Therapeutic Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Teva Pharmaceutical Industries Ltd.,
10.2.2. Novartis AG
10.2.3. GlaxoSmithKline Plc.
10.2.4. AbbVie Inc.
10.2.5. Merck & Co. Inc.,
10.2.6. Zydus Cadila
10.2.7. Dr. Reddy's
10.2.8. Sun Pharmaceutical Industries Ltd.
10.2.9. Cipla Inc.
10.2.10. Boehringer Ingelheim International GmbH
10.2.11. Denali Therapeutics Inc.
10.2.12. Biogen Inc.
10.2.13. Prevail Therapeutics
10.2.14. Eli Lilly and Company
10.2.15. Voyager Therapeutics.
10.2.16. Intas Pharmaceuticals Ltd.
10.2.17. Torrent Pharmaceuticals Ltd.
10.2.18. Amneal Pharmaceuticals
10.2.19. Aurobindo Pharma Limited
10.2.20. Accord Healthcare Ltd.
10.2.21. Other Prominent Market Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們